
Pfizer inks deal with China's 3SBio
US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met. Pfizer also plans to make a $100 million equity …